A Phase 2 interventional study of INCB019602 and INCB019602 in Type 2 Diabetes, sponsored by Incyte Corporation. Terminated at 22 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-10-30.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 48 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Incyte Corporation is the lead sponsor of 286 studies on the registry; 37 are open to participants now.
Of its 144 completed or terminated interventional studies of FDA-regulated products, 93 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
5 mg of INCB019602 in AM with placebo administration in PM
Drug: INCB019602 · Drug: Placebo · Drug: Metformin
20 mg of INCB019602 in AM with placebo administration in PM
Drug: INCB019602 · Drug: Placebo · Drug: Metformin
5 mg of INCB019602 in PM with placebo administration in AM
Drug: INCB019602 · Drug: Placebo · Drug: Metformin
20 mg of INCB019602 in PM with placebo administration in AM
Drug: INCB019602 · Drug: Placebo · Drug: Metformin
7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
Drug: INCB019602 · Drug: Placebo · Drug: Metformin
Placebo BID
Drug: Placebo · Drug: Metformin
5 mg of INCB019602 in AM with placebo administration in PM
20 mg in AM with placebo administration in PM
5 mg in PM with placebo administration in AM
20 mg in PM with placebo administration in AM
7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
Placebo administration in AM or PM depending on treatment arm dosing regimen.
Stable dose metformin monotherapy
Safety and tolerability as determined by monitoring of AEs, vital signs, ECGs, physical examinations, and clinical laboratory blood and urine parameters.
Time frame: End of Study
Change from Baseline in fasting plasma glucose and population pharmacokinetics of INCB019602 in type 2 diabetic patients.
Time frame: End of Study
This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Incyte Corporation